Clinical trials referenced in this document:
Documents that mention this clinical trial
24-Month Efficacy and Safety Results from Japanese Patients in the IMPERIAL Randomized Study of the Eluvia Drug-Eluting Stent and the Zilver PTX Drug-Coated Stent
Japanese Patients Treated in the IMPERIAL Randomized Trial Comparing Eluvia and Zilver PTX Stents
Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent
Funding for this research was provided by:
Boston Scientific Corporation
Received: 13 August 2020
Accepted: 21 October 2020
First Online: 22 November 2020
Compliance with Ethical Standards
: Stefan Müller-Hülsbeck, MD, PhD serves as a consultant and has received honoraria and travel grants from Boston Scientific, and has received fees from Terumo. Andrew Benko, MD reports receiving research funding from Medtronic and Soundbite Medical, is a shareholder in Soundbite Medical, and has received speaking fees from Medtronic, Cordis, and Boston Scientific. Yoshimitsu Soga, MD serves as an advisor to Boston Scientific. Masahiko Fujihara, MD reports consulting for Boston Scientific. Osamu Iida, MD reports consulting for Boston Scientific. Anvar Babaev, MD reports receiving honoraria for physician training from Boston Scientific, Abbott, Medtronic, and Cook. David O’Connor, MD reports receiving honoraria for physician training from Cardiovascular Systems Incorporated, Abbott, and Boston Scientific. Thomas Zeller, MD reports receiving honoraria from: Abbott Vascular, Veryan, Biotronik, Boston Scientific Corp., Cook Medical, Gore & Associates, Medtronic, Philips-Spectranetics, TriReme, Veryan, Shockwave, Biotronik, B. Braun, Efemoral, consulting for: Boston Scientific Corp., Cook Medical, Gore & Associates, Medtronic, Spectranetics, Veryan, Intact Vascular, Veryan. and holding common stock in: QT Medical. Daniel D. Dulas, MD declares that he has no conflict of interest. Juan Diaz-Cartelle, MD is an employee of and owns stock in Boston Scientific. William A. Gray, MD serves as an advisor to Boston Scientific.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was approved by the applicable Institutional Review Board (IRB), ethics committee, or research ethics board for each study site.
: Informed consent was obtained from all individual participants included in the study.
: For this type of study, consent for publication is not required.